☆ 4.5 Article

Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: A discrete choice experiment

Kate A. Carey et al.

Summary: This study aimed to understand the factors that influence decision-making in the treatment of infantile spinal muscular atrophy (SMA). The results showed that treatments with a higher chance of improving functioning and mobility were preferred, while treatments with higher costs, invasive delivery, and risk of adverse events were less preferred. The study also revealed that cost influenced treatment choices for healthcare professionals and the general population, while change in mobility and mode of administration were most influential for parents.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screening

Stella Deng et al.

Summary: Treatment frequency and administration method were the most important factors for parents in determining spinal muscular atrophy treatment. Parents felt positively about newborn screening due to opportunity for earlier treatment.

JOURNAL OF CHILD NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA

Dylan Trundell et al.

Summary: This study developed an independence scale for individuals with Type 2 and non-ambulant Type 3 spinal muscular atrophy. The results support the reliability and validity of the scale, which can be used to assess the level of assistance required for daily activities in patients.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial

Eugenio Mercuri et al.

Summary: Risdiplam has shown significant improvement in motor function compared to placebo in patients with type 2 or non-ambulant type 3 spinal muscular atrophy. Motor function generally improved in younger patients and stabilized in older patients.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Genetics & Heredity

Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy

Eve Fouarge et al.

Summary: The study presents a Bayesian model that utilizes each patient's own natural history data to predict disease progression and compares it with actual post-treatment outcomes. By analyzing forced expiratory volume in 1 s (FEV1) in children aged 6-18, the study identified responders based on clinical relevance criteria and predictive probabilities. This approach provides a powerful trial design to address the challenges posed by the rarity and genetic heterogeneity of centronuclear myopathies.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Review Genetics & Heredity

Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments

Tamara Dangouloff et al.

Summary: The review summarizes studies on the cost of caring for spinal muscular atrophy (SMA) patients and economic evaluations of treatments, revealing a substantial cost burden of standard care for SMA patients and high cost-effectiveness ratios of approved drugs in post-symptomatic patients at current prices. Additional prospective and independent economic studies in pre- and post-symptomatic patients are needed due to the limited number of conducted studies.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study

Melanie Annoussamy et al.

Summary: Upper limb activity and strength began to significantly decline at 12 months and continued to decrease at 24 months, while motor function scores significantly declined at 24 months. Pulmonary function significantly declined at 12 months, while blood SMN protein levels remained stable at 12 and 24 months.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy

Robert C. Sergott et al.

Summary: Evaluation of ophthalmologic safety in patients with spinal muscular atrophy (SMA) treated with risdiplam showed no retinal structural or functional changes, suggesting that safety ophthalmologic monitoring is not needed in these patients.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri et al.

Summary: The STR1VE-EU study evaluated the safety and efficacy of onasemnogene abeparvovec gene replacement therapy in infants with spinal muscular atrophy type 1, showing effectiveness in symptomatic patients and a favorable benefit-risk profile for this patient population. Further long-term safety studies are needed.

LANCET NEUROLOGY (2021)

添加到收藏夹

Meeting Abstract Clinical Neurology

JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naive patients with spinal muscular atrophy (SMA) receiving risdiplam

C. Chiriboga et al.

NEUROMUSCULAR DISORDERS (2021)

添加到收藏夹

Article Medicine, General & Internal

Risdiplam in Type 1 Spinal Muscular Atrophy

Giovanni Baranello et al.

Summary: In a study involving 21 infants with type 1 spinal muscular atrophy, treatment with oral risdiplam resulted in increased levels of functional SMN protein in the blood. Infants in the high-dose group were more likely to sit without support for at least 5 seconds, and the higher dose of risdiplam was selected for the second part of the study.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium

Francois Boemer et al.

Summary: Three new therapies for SMA have been approved by FDA and EMA since 2016, with emphasis on early administration before symptoms. A pilot program in Belgium successfully transitioned into an official neonatal screening program, providing valuable lessons for newborn screening.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities

Laurent Servais et al.

Summary: The current drug treatments for SMA cannot cure the disease, and there remains a significant unmet need for patients treated after symptom onset. Clinical development of new drugs for SMA is challenging due to the heterogeneity of the patient population, variability in response to initial therapy, age at treatment onset, and the requirement to demonstrate added value beyond approved therapeutics.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Clinical Neurology

Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go

Tamara Dangouloff et al.

Summary: The study provides a global overview on the current situation and perspectives on SMA NBS, pointing out the differences in funding, screening methods, organization, and consent process between countries. Experts expressed a strong need for the implementation of SMA NBS to improve patient care.

NEUROMUSCULAR DISORDERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Metabolic Dysfunction in Spinal Muscular Atrophy

Marc-Olivier Deguise et al.

Summary: Spinal muscular atrophy (SMA) is a genetic disorder causing paralysis, muscle atrophy, and death. Recent research suggests that gastrointestinal, metabolic, and endocrine defects may contribute to the disease phenotype.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

Basil T. Darras et al.

Summary: In this study involving infants with type 1 SMA, treatment with risdiplam resulted in higher percentages of infants who achieved motor milestones and showed improvements in motor function compared to historical controls. Longer and larger trials are needed to confirm the long-term safety and efficacy of risdiplam in infants with type 1 SMA.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Clinical Neurology

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy

Charlotte Lilien et al.

Summary: By using quantitative MRI and functional assessments, continuous decline in upper limb strength and function in DMD patients can be reliably measured, with important implications for detecting and predicting important motor milestones.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

添加到收藏夹

Review Orthopedics

Risdiplam for the Use of Spinal Muscular Atrophy

Juyeon Kakazu et al.

Summary: Currently, Risdiplam is the only orally administered drug approved by the FDA for the treatment of SMA, providing stronger systemic therapies and allowing for a non-invasive approach in infants. Further investigation and comparison on the safety profile of Risdiplam due to its broader systemic effect should be considered with other available therapies.

ORTHOPEDIC REVIEWS (2021)

添加到收藏夹

Article Clinical Neurology

244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands

Tamara Dangouloff et al.

NEUROMUSCULAR DISORDERS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

New treatments in spinal muscular atrophy: an overview of currently available data

Sithara Ramdas et al.

EXPERT OPINION ON PHARMACOTHERAPY (2020)

添加到收藏夹

Review Clinical Neurology

Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease

Crystal Jing Jing Yeo et al.

PEDIATRIC NEUROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?

Maria Carmela Pera et al.

PLOS ONE (2020)

添加到收藏夹

Article Clinical Neurology

Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

Tim Hagenacker et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Risdiplam: First Approval

Sohita Dhillon

DRUGS (2020)

添加到收藏夹

Article Clinical Neurology

Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial

Francesco Muntoni et al.

NEUROMUSCULAR DISORDERS (2020)

添加到收藏夹

Review Neurosciences

The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy

Ravindra N. Singh et al.

NEUROSCIENCE INSIGHTS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural basis of a small molecule targeting RNA for a specific splicing correction

Sebastien Campagne et al.

NATURE CHEMICAL BIOLOGY (2019)

添加到收藏夹

Article Health Care Sciences & Services

Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives

Tamara Dangouloff et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

Stefan Sturm et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

Hasane Ratni et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study

Aurelie Chabanon et al.

PLOS ONE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

Agnes Poirier et al.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy

Emmanuel Pinard et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

Enrico Bertini et al.

LANCET NEUROLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

R. S. Finkel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Genetics & Heredity

Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review

Ingrid E. C. Verhaart et al.

ORPHANET JOURNAL OF RARE DISEASES (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers

Manaswini Sivaramakrishnan et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Clinical Neurology

Natural history of infantile-onset spinal muscular atrophy

Stephen J. Kolb et al.

ANNALS OF NEUROLOGY (2017)

添加到收藏夹

Article Chemistry, Medicinal

Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy

Hasane Ratni et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Clinical Neurology

Developmental milestones in type I spinal muscular atrophy

Roberto De Sanctis et al.

NEUROMUSCULAR DISORDERS (2016)

添加到收藏夹

Article Clinical Neurology

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study

Stephen J. Kolb et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)

添加到收藏夹

Article Neurosciences

Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy

Sarah Tisdale et al.

JOURNAL OF NEUROSCIENCE (2015)

添加到收藏夹

Review Anatomy & Morphology

Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Monir Shababi et al.

JOURNAL OF ANATOMY (2014)

添加到收藏夹

Article Clinical Neurology

Observational study of spinal muscular atrophy type I and implications for clinical trials

Richard S. Finkel et al.

NEUROLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy

Nikolai A. Naryshkin et al.

SCIENCE (2014)

添加到收藏夹

Review Clinical Neurology

Childhood spinal muscular atrophy: controversies and challenges

Eugenio Mercuri et al.

LANCET NEUROLOGY (2012)

添加到收藏夹

Article Clinical Neurology

DIGITAL NECROSES AND VASCULAR THROMBOSIS IN SEVERE SPINAL MUSCULAR ATROPHY

Sabine Rudnik-Schoeneborn et al.

MUSCLE & NERVE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.